Breaking 23:40 Artificial Intelligence in Perfumery: How Technology Is Transforming the Art of Fragrance Creation 23:30 Morocco: Moves Closer to Acquiring US KC-10 Extender Aerial Refueling Aircraft 23:00 Simple Share: Simple Launches a New Referral Programme to Reward Customer Recommendations in Morocco 22:30 Morocco: Egg Prices Hit MAD 1.50 as Fuel Costs and Lower Production Drive Increase 22:00 Morocco U20: Atlas Cubs Beat Ivory Coast 1-0 in Friendly Ahead of AFCON Preparations 21:30 African Healthcare: Morocco Highlights Its Experience in Bordeaux 21:00 Nvidia Leadership Crisis: Jensen Huang Offers to Return as CEO 20:30 Israel: 20 Humanitarian Aid Trucks Bound for Gaza to Undergo Daily Inspections at Erez Crossing 20:00 Morocco: CESE Embraces Artificial Intelligence With Two Digital Avatars 19:30 Morocco: DGSN Strengthens Security Measures With New Facilities in Marrakech and Beni Mellal 19:00 Casablanca: New Mobile Emergency Police Unit Strengthens Security in Hay Hassani 18:30 Spain: Fan Sentenced for Racist Abuse Targeting Kylian Mbappé 18:00 Morocco: ADII Announces Exceptional Customs Duty Service Nationwide on November 18 17:30 Tamwilcom: Morocco Wins International Recognition at the Startup Ecosystem Stars Awards 2026 17:00 AC Milan: Noussair Mazraoui Back on the Club's Radar Ahead of the January Transfer Window 16:53 Capgemini Reveals Five Technology Trends Set to Transform Businesses by 2027 16:30 EU Sanctions Gaza Now: Palestinian Media Outlet and Founder Targeted Over Alleged Hamas Funding 16:28 Morocco: DGSN Launches New Crowd-Control Brigade to Strengthen Public Security in Salé 16:00 Tebboune: The Story of a President Who Built His Glory on Threats Against Morocco 15:45 Sahara Dispute: US Reaffirms Commitment to a Lasting Settlement and Support for Morocco's Autonomy Initiative 15:30 Spain: Public Debt Hits Record €1.767 Trillion, Reaching 100.3% of GDP 15:12 Atlas Lions: Moroccan Players Receive MAD 13 Million in Combined AFCON and World Cup Bonuses 15:00 Morocco Makes History: Four Arab Golf Titles at the 2026 Pan Arab Championship 14:45 Israel Politics: Eisenkot’s Bloc Moves to Take Knesset Speakership From Likud 14:30 Qatar 2026: Morocco U17 Set for Three Crucial Group-Stage Matches at the World Cup 14:00 Morocco–US Cooperation: Forensic Experts Strengthen Criminal Investigation Capabilities 13:30 Morocco's Diabetes Crisis: Nearly 2.9 Million People Affected as Economic Costs Reach 3.8% of GDP 13:00 France: Hundreds of Troops Could Be Deployed to Lebanon as UNIFIL Withdrawal Approaches 12:30 Bahrain: Multiple Iranian Aerial Attacks Intercepted Amid Rising Regional Tensions 12:15 US Navy: Expands Middle East Deployment Beyond March Levels Amid Iran Tensions 12:12 Dakhla Global Summit 2026: African Leaders and Scientists Unite for Health Sovereignty 12:00 Iranian Threats: US Intelligence Warns of Potential Attacks Against Trump Administration Officials 11:45 Morocco in Doha: Royal Atlantic Initiative Promoted as a Strategic Tool for Peace and Stability in Africa 11:30 Morocco: Automatic Mobile Roaming and Satellite Internet to Improve Connectivity in Remote Areas 11:15 Morocco: First Cannabis-Based Medicine Marks a New Era for Pharmaceutical Innovation 11:00 Libya: 67 Moroccan Migrants Remain Detained as Repatriation Efforts Face Delays 10:45 New York: Mamdani Orders Dismantling of NYPD Unit Criticised Over Protest Crackdowns 10:30 MINURSO Withdrawal: First UN Military Contingent Leaves Laayoune as Mission Enters Closure Phase 10:15 Australia: Doctor Leaves Sydney Hospital Following Antisemitism Complaint 10:00 Israel: Knesset Leadership Vote Faces Potential Delay as Likud Seeks to Block Opposition Move 09:45 Gaza War: Report Reveals Israeli Military's Use of Amazon AI to Identify Palestinians 09:30 Reflect Orbital: The American Startup Planning to Bring Sunlight to Earth at Night 09:15 Morocco Education Reform: Minister Exposes Major Challenges Facing Public Schools 09:00 Morocco: FRMF Steps Up European Talent Recruitment as 19 Dual Nationals Choose the Atlas Lions 08:45 Corma: AI Cybersecurity Startup Reaches $1 Billion Valuation After Raising $125 Million 08:30 Israel: Likud Accuses Gadi Eisenkot of Seeking Arab Party Support to Block a National Unity Government

Personalized mRNA vaccine keeps most breast cancer patients in remission

Thursday 19 February 2026 - 07:20
By: Dakir Madiha
Personalized mRNA vaccine keeps most breast cancer patients in remission

An individualized mRNA vaccine has kept most women with triple negative breast cancer in long term remission, according to results published in Nature, offering new evidence that tailored immunotherapy may provide durable protection against one of the most aggressive forms of the disease.

The study, released on February 17, 2026, found that 11 of 14 patients treated with a personalized mRNA vaccine remained cancer free for up to six years after therapy. Ten participants were still without evidence of disease at the time of analysis. The early phase trial tested vaccines designed specifically for each patient, targeting mutated proteins unique to their tumors in order to stimulate a focused immune response.

Researchers reported that 86 percent of heavily pretreated patients developed strong neoantigen specific immune responses. Neoantigens are abnormal proteins produced by tumor specific mutations, making them distinct from healthy tissue and ideal targets for precision immunotherapy. By encoding these neoantigens into customized mRNA sequences, the vaccine trained the immune system to identify and attack cancer cells carrying those mutations.

The findings indicate that vaccine induced T cells expanded to measurable levels within circulating immune cells, representing a substantial anti tumor response. Importantly, the study showed that these T cells matured into two complementary forms: cytotoxic effector cells capable of directly destroying tumor cells, and stem like memory cells able to persist over time and regenerate the immune response.

This dual development is considered critical for sustained cancer control. Effector cells provide immediate tumor killing capacity, while memory cells maintain long term immune surveillance, reducing the likelihood of relapse. In this trial, T cell responses remained detectable for up to six years after vaccination, suggesting that the therapy can establish prolonged immune protection.

Three patients experienced a recurrence of their cancer, offering insights into how tumors may evade immune defenses. In one case, the recurrent tumor exhibited downregulation of major histocompatibility complex class I molecules, a recognized mechanism that allows cancer cells to escape detection by T cells. Such immune escape pathways remain a key challenge in oncology and highlight the need for combination approaches that reinforce immune recognition.

Triple negative breast cancer accounts for approximately 15 to 20 percent of all breast cancer cases. It is defined by the absence of estrogen receptors, progesterone receptors and HER2 expression, making it unresponsive to hormonal or HER2 targeted therapies. Patients with this subtype face a recurrence rate of roughly 40 percent within five years, underscoring the need for new preventive strategies following initial treatment.

The personalized mRNA vaccine approach aims to reduce relapse risk by establishing robust anti tumor immunity before residual cancer cells can reemerge. Unlike conventional therapies that broadly target rapidly dividing cells, this strategy uses genetic sequencing of each patient’s tumor to identify mutations and design a vaccine tailored to those specific alterations.

The research builds on earlier work involving individualized neoantigen vaccines in other cancers. BioNTech and Genentech are developing autogene cevumeran, a personalized mRNA therapy targeting tumor specific neoantigens, which has shown promising results across several solid tumors. Previous trials demonstrated that the platform can induce poly epitope immune responses involving both CD4 positive helper T cells and CD8 positive cytotoxic T cells in most treated patients.

While the current findings are based on a small cohort, investigators say the durability of the immune responses and the extended remission observed in most participants support further clinical development. Larger randomized trials will be required to confirm efficacy and determine whether personalized mRNA vaccination can become part of standard treatment for high risk breast cancer patients.

The results contribute to growing evidence that mRNA technology, initially deployed at scale during the COVID 19 pandemic, can be adapted for precision oncology. By harnessing the immune system to recognize each tumor’s unique mutation profile, researchers hope to shift cancer care toward long term immune control rather than repeated cycles of relapse and treatment.


  • Fajr
  • Sunrise
  • Dhuhr
  • Asr
  • Maghrib
  • Isha

This website, walaw.press, uses cookies to provide you with a good browsing experience and to continuously improve our services. By continuing to browse this site, you agree to the use of these cookies.